Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 23;6(1):e12110.
doi: 10.1002/trc2.12110. eCollection 2020.

Model organism development and evaluation for late-onset Alzheimer's disease: MODEL-AD

Adrian L Oblak  1   2 , Stefania Forner  3 , Paul R Territo  1   2 , Michael Sasner  4 , Gregory W Carter  4 , Gareth R Howell  4 , Stacey J Sukoff-Rizzo  5 , Benjamin A Logsdon  6 , Lara M Mangravite  6 , Ali Mortazavi  3 , David Baglietto-Vargas  3 , Kim N Green  3 , Grant R MacGregor  3 , Marcelo A Wood  3 , Andrea J Tenner  3 , Frank M LaFerla  3 , Bruce T Lamb  1   2 ; and The MODEL‐AD; Consortium
Affiliations

Model organism development and evaluation for late-onset Alzheimer's disease: MODEL-AD

Adrian L Oblak et al. Alzheimers Dement (N Y). .

Abstract

Alzheimer's disease (AD) is a major cause of dementia, disability, and death in the elderly. Despite recent advances in our understanding of the basic biological mechanisms underlying AD, we do not know how to prevent it, nor do we have an approved disease-modifying intervention. Both are essential to slow or stop the growth in dementia prevalence. While our current animal models of AD have provided novel insights into AD disease mechanisms, thus far, they have not been successfully used to predict the effectiveness of therapies that have moved into AD clinical trials. The Model Organism Development and Evaluation for Late-onset Alzheimer's Disease (MODEL-AD; www.model-ad.org) Consortium was established to maximize human datasets to identify putative variants, genes, and biomarkers for AD; to generate, characterize, and validate the next generation of mouse models of AD; and to develop a preclinical testing pipeline. MODEL-AD is a collaboration among Indiana University (IU); The Jackson Laboratory (JAX); University of Pittsburgh School of Medicine (Pitt); Sage BioNetworks (Sage); and the University of California, Irvine (UCI) that will generate new AD modeling processes and pipelines, data resources, research results, standardized protocols, and models that will be shared through JAX's and Sage's proven dissemination pipelines with the National Institute on Aging-supported AD Centers, academic and medical research centers, research institutions, and the pharmaceutical industry worldwide.

Keywords: Alzheimer's disease; LOAD; MRI; Open Science; PET; animal models; preclinical.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Workflow for creating and testing novel animal models of late‐onset Alzheimer's disease
FIGURE 2
FIGURE 2
Role of the MODEL‐AD center in the system of NIH‐funded consortia created to discover new treatments for Alzheimer's disease. AD, Alzheimer's disease; ADNI, Alzheimer's Disease Neuroimaging Initiative; ADSP, Alzheimer's Disease Sequencing Project; AMP‐AD, Accelerating Medicines Partnerships–Alzheimer's Disease; MODEL‐AD, Model Organism Development and Evaluation for Late‐onset Alzheimer's Disease; M2OVE‐AD, Molecular Mechanisms of the Vascular Etiology of Alzheimer's Disease.
FIGURE 3
FIGURE 3
Workflow for testing compounds through the Preclinical Testing Core. API, active pharmaceutical ingredient; IU, Indiana University; MRI, magnetic resonance imaging; PET, positron emission tomography; PITT, University of Pittsburgh School of Medicine; PK, pharmokinetic; QC, quality control.
See this image and copyright information in PMC

References

    1. James BD, Leurgans SE, Hebert LE, Scherr PA, Yaffe K, Bennett DA. Contribution of Alzheimer disease to mortality in the United States. Neurology. 2014;82(12):1045‐1050. - PMC - PubMed
    1. Alzheimer's A 2019 https://www.alz.org/media/documents/alzheimers-facts-and-figures-2019-r.pdf
    1. Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368(2):117‐127. - PMC - PubMed
    1. Lannfelt L, Relkin NR, Siemers ER. Amyloid‐ss‐directed immunotherapy for Alzheimer's disease. J Intern Med. 2014;275(3):284‐295. - PMC - PubMed
    1. De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol. 2010;6(2):99‐107. - PMC - PubMed